Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAF1 | P04049 | 11/20 | 0.59 |
| ▸ | EPHX2 | P34913 | 4/20 | 0.59 |
| ▸ | KDR | P35968 | 6/20 | 0.57 |
| ▸ | MAPK14 | Q16539 | 5/20 | 0.57 |
| ▸ | ABL1 | P00519 | 3/20 | 0.57 |
| ▸ | RET | P07949 | 3/20 | 0.57 |
| ▸ | EPHA2 | P29317 | 3/20 | 0.57 |
| ▸ | MAP3K20 | Q9NYL2 | 3/20 | 0.57 |
| ▸ | PLK4 | O00444 | 2/20 | 0.57 |
| ▸ | AURKA | O14965 | 2/20 | 0.57 |
| ▸ | MAPK13 | O15264 | 2/20 | 0.57 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.57 |
| ▸ | LCK | P06239 | 2/20 | 0.57 |
| ▸ | FYN | P06241 | 2/20 | 0.57 |
| ▸ | LYN | P07948 | 2/20 | 0.57 |
| ▸ | SRC | P12931 | 2/20 | 0.57 |
| ▸ | RPS6KB1 | P23443 | 2/20 | 0.57 |
| ▸ | AXL | P30530 | 2/20 | 0.57 |
| ▸ | FRK | P42685 | 2/20 | 0.57 |
| ▸ | MAPK9 | P45984 | 2/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4181174 | 0.92 | RET (0.56) | RAF1EPHX2KDRMAPK14ABL1 | |
| SCHEMBL4173358 | 0.90 | RAF1 (0.52) | RAF1EPHX2KDRMAPK14ABL1 | |
| SCHEMBL13603524 | 0.88 | DDR2 (0.53) | RAF1EPHX2KDRMAPK14BRAF | |
| SCHEMBL938402 | 0.85 | RAF1 (0.58) | RAF1KDRMAPK14MAPK13TNNI3K | |
| SCHEMBL4185779 | 0.85 | RAF1 (0.58) | RAF1KDRBRAFMEN1KMT2A | |
| SCHEMBL2328292 | 0.84 | RAF1 (0.49) | RAF1KDRBRAFPDGFRAMEN1 | |
| SCHEMBL12391532 | 0.82 | RAF1 (0.76) | RAF1EPHX2KDRMAPK14ABL1 | |
| SCHEMBL257980 | 0.82 | RAF1 (0.82) | RAF1EPHX2KDRMAPK14ABL1 | |
| SCHEMBL12719566 | 0.82 | RAB9A (0.46) | RAF1KDRMAPK14ABL1RET | |
| SCHEMBL16621444 | 0.80 | RAF1 (0.68) | RAF1EPHX2KDRMAPK14ABL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4359817-B2 | — | — | 2009-11-11 | — | — | JP | claimed |
| JP-2004537511-A | — | — | 2004-12-16 | — | — | JP | claimed |
| EP-1379507-A1 | HETEROARYL UREAS CONTAINING NITROGEN HETERO-ATOMS AS p38 KINASE INHIBITORS | Bayer Corporation (US) | 2004-01-14 | — | — | EP | claimed |
| WO-2002085859-A1 | HETEROARYL UREAS CONTAINING NITROGEN HETERO-ATOMS AS p38 KINASE INHIBITORS | BAYER CORPORATION (US) | 2002-10-31 | — | — | WO | claimed |
| US-20020065296-A1 | Heteroaryl ureas containing nitrogen hetero-atoms as p38 kinase inhibitors | BAYER CORPORATION | 2002-05-30 | — | — | US | claimed |
| EP-2386545-A1 | Heteroaryl ureas containing nitrogen hetero-atoms as P38 kinase inhibitors | Bayer Healthcare LLC (US) | 2011-11-16 | — | — | EP | disclosed |
| EP-1379507-B1 | HETEROARYL UREAS CONTAINING NITROGEN HETERO-ATOMS AS p38 KINASE INHIBITORS | BAYER HEALTHCARE LLC (US) | 2011-08-17 | — | — | EP | disclosed |
| US-7928239-B2 | Anticarcinogenic agents | BAYER HEALTHCARE LLC (US) | 2011-04-19 | — | — | US | disclosed |
| US-7928239-B2 | Anticarcinogenic agents | BAYER HEALTHCARE LLC (US) | 2011-04-19 | — | — | US | disclosed |
| US-20080194580-A1 | Inhibition Of Raf Kinase Using Quinolyl, Isoquinolyl Or Pyridyl Ureas | BAYER HEALTHCARE LLC | 2008-08-14 | — | — | US | disclosed |
| US-20080194580-A1 | Inhibition Of Raf Kinase Using Quinolyl, Isoquinolyl Or Pyridyl Ureas | BAYER HEALTHCARE LLC | 2008-08-14 | — | — | US | disclosed |
| US-7371763-B2 | Inhibition of raf kinase using quinolyl, isoquinolyl or pyridyl ureas | BAYER PHARMACEUTICALS CORPORATION (US) | 2008-05-13 | — | — | US | disclosed |
| US-7371763-B2 | Inhibition of raf kinase using quinolyl, isoquinolyl or pyridyl ureas | BAYER PHARMACEUTICALS CORPORATION (US) | 2008-05-13 | — | — | US | disclosed |
| EP-1379505-B1 | INHIBITION OF RAF KINASE USING QUINOLYL, ISOQUINOLYL OR PYRIDYL UREAS | BAYER PHARMACEUTICALS CORP (US) | 2007-02-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080194580-A1 | Inhibition Of Raf Kinase Using Quinolyl, Isoquinolyl Or Pyridyl Ureas | BRAF, RAF1, ARAF | RAF1 2/4885EPHX2 2567/4885KDR 1420/4885 |
| US-20020065296-A1 | Heteroaryl ureas containing nitrogen hetero-atoms as p38 kinase inhibitors | MAPK1, MAP3K1, MAPK3 | RAF1 246/4885EPHX2 2821/4885KDR 1661/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.